Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?

Cancer discovery - 1 Sept 2014

Peng Guang, Woodman Scott E, Mills Gordon B

Abstract excerpt

SUMMARY: In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acid Anhydride Hydrolases
Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to DNA Repair Enzymes

Share to RAD50 gene

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25185187
DOI: 10.1158/2159-8290.CD-14-0738
PMCID: PMC4155513

Genes

RAD50

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?PMID 25185187Read ↗

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.Semantic proximity Read ↗

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.Semantic proximity Read ↗

What have we learned from exceptional tumour responses?: Review and perspectives.Semantic proximity Read ↗

Molecular Profiling of Exceptional Responders to Cancer Therapy.Semantic proximity Read ↗

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.Semantic proximity Read ↗

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsSemantic proximity Read ↗

Mapping the human kinome in response to DNA damageSemantic proximity Read ↗

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM.Semantic proximity Read ↗

The Yin and Yang of treating BRCA-deficient tumors.Semantic proximity Read ↗

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.Semantic proximity Read ↗

Anticipating on-target resistance to WRN inhibitors in microsatellite unstable cancersSemantic proximity Read ↗

Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.